Last updated 40 days ago

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

2200 patients around the world

Available in Argentina, Chile, Puerto Rico, United States, Peru

This is a randomized, double-blind, double dummy, parallel group, multicenter 24 to 52 week variable length study to assess the efficacy and safety of budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler (MDI) relative to budesonide and formoterol fumarate MDI and Symbicort® pressurized MDI in adult and adolescent participants with inadequately controlled asthma. Approximately 2200 participants will be randomized globally.

AstraZeneca

3Research sites

2200Patients around the world

This study is for people with

Asthma

Requirements for the patient

To 80 Years

All Gender

Medical requirements

Sites

InAER - Investigaciones en Alergia y Enfermedades Respiratorias - CABA, Buenos Aires

Recruiting

Arenales 3146, CABA, Buenos Aireshttp://www.inaerargentina.org/

Sala de Primeros Auxilios Alberto Mignaburu - Berazategui, Prov Buenos Aires

Recruiting

Av. Antartida Argentina entre calle 257 y camino Gral Belgrano S/N, Berazategui Buenos Aireshttps://www.facebook.com/fundacionrespirarsalud

Consultorios Médicos del Buen Ayre

Recruiting

Fitz Roy 2468 1er Piso, C1425FVH CABA, Argentina

StudyKALOS

SponsorAstraZeneca

Study typeInterventional

Conditions

Requirements

To 80 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT04609878